All manuscripts
Publications CAR T Cells G-Rex®6 Well Plate

Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR/CXCR5 T cells

Published Journal Frontiers in Immunology

Share
13 pages Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR/CXCR5 T cells — Frontiers in Immunology, 2022

Overview

This study monitored anti-CAR antibody responses in rhesus macaques infused with CD4-MBL CAR/CXCR5 T cells. The therapeutic cells were expanded in G-Rex® 6-well plates prior to infusion. All treated animals developed anti-CAR antibodies, which correlated with limited in vivo persistence of the CAR T cells.

What this paper found

All nine rhesus macaques infused with SIV-specific CD4-MBL CAR/CXCR5 T cells developed anti-CAR IgG antibodies in serum, detected by a flow cytometry binding assay. Binding at 28 days after treatment ranged from 0.5% to 27% of target cells, and control animals showed none. Blocking CD4 with an antibody reduced or eliminated binding in all six animals tested, which points to the CD4 domains as the main antigenic site. Binding to CAR targets with the CD28 extracellular domain replaced was lower with serum from 2 of 3 animals. Most sera also triggered NK-cell degranulation in an ADCC assay. Antibody levels did not correlate significantly with CAR T cell persistence or with infused dose.

Note: Preclinical study in rhesus macaques; the authors note that additional animals may be needed to assess the effect of the anti-drug antibody response on in vivo persistence.

This study shows that an anti-drug antibody (ADA) response can occur even when using self-proteins, likely due to novel epitopes created by abridged self-proteins — Brianna C. Davey, Mary S. Pampusch, Emily K. Cartwright, Hadia M. Abdelaal, Eva G. Rakasz, Aaron Rendahl, Edward A. Berger, Pamela J. Skinner, Frontiers in Immunology

Study details

Authors
Brianna C. Davey, Mary S. Pampusch, Emily K. Cartwright, Hadia M. Abdelaal, Eva G. Rakasz, Aaron Rendahl, Edward A. Berger, Pamela J. Skinner
Institution
Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN, United States · Wisconsin National Primate Research Center, University of Wisconsin, Madison, Madison, WI, United States · Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
Journal
Frontiers in Immunology
Year
2022
PMID / PMC
PMID: 36582226 · PMC
G-Rex® model(s)
G-Rex®6 Well Plate
Cell type(s)
CAR T Cells
Application area
Infectious disease
Study phase
Preclinical

How G-Rex® was used

Rhesus PBMCs were stimulated with anti-CD3 and anti-CD28 for two days and transduced with the CD4-MBL CAR/CXCR5 gammaretroviral vector. The transduced cells were then placed in G-Rex® 6 well plates and expanded for 4 days before infusion into rhesus macaques.

Note: Mock-transduced cells underwent the same stimulation and expansion without exposure to the gammaretroviral vectors.

Explore related

Full citation

Davey BC, Pampusch MS, Cartwright EK, et al. Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR/CXCR5 T cells. Front Immunol. 2022;13:1032537.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →